Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Vertex Pharmaceuticals, Inc, Cambridge, Massachusetts, USA.
Ann D
AD
Kwong
Isabel
I
Najera
Jill
J
Bechtel
Scott
S
Bowden
Joseph
J
Fitzgibbon
Patrick
P
Harrington
Dale
D
Kempf
Tara L
TL
Kieffer
Diana
D
Koletzki
George
G
Kukolj
Sharlene
S
Lim
Tami
T
Pilot-Matias
Kai
K
Lin
Nina
N
Mani
Hongmei
H
Mo
Jules
J
O'Rear
Michael
M
Otto
Neil
N
Parkin
Jean-Michel
JM
Pawlotsky
Chris
C
Petropoulos
Gaston
G
Picchio
Robert
R
Ralston
Jacqueline D
JD
Reeves
Robert T
RT
Schooley
Scott
S
Seiwert
David
D
Standring
Lieven
L
Stuyver
James
J
Sullivan
Veronica
V
Miller
D000998:Antiviral Agents / Q000627:therapeutic use*; D055808:Drug Discovery / Q000592:standards*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D010641:Phenotype; D017211:Treatment Failure
D000998:Antiviral Agents